Assertio Therapeutics, Inc. (ASRT)
| Market Cap | 68.57M |
| Revenue (ttm) | 135.33M |
| Net Income (ttm) | -196.42M |
| Shares Out | 119.56M |
| EPS (ttm) | -2.07 |
| PE Ratio | n/a |
| Forward PE | 5.36 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 19 |
| Last Price | $0.640 |
| Previous Close | $0.590 |
| Change ($) | 0.049 |
| Change (%) | 8.37% |
| Day's Open | 0.598 |
| Day's Range | 0.590 - 0.640 |
| Day's Volume | 6,922,843 |
| 52-Week Range | 0.340 - 1.080 |
Investors need to pay close attention to Assertio Holdings (ASRT) stock based on the movements in the options market lately.
Company Receives additional 180-day grace period, until June 28, 2021, to satisfy the $1.00 bid price requirement to maintain Nasdaq listing
LAKE FOREST, Ill., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, announced that President, ...
Assertio Holdings, Inc. (ASRT) CEO Todd Smith on Q3 2020 Results - Earnings Call Transcript
Assertio (ASRT) delivered earnings and revenue surprises of 100.00% and 6.34%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LAKE FOREST, Ill., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, announced that the comp...
Assertio Holdings, Inc. (ASRT) CEO Todd Smith on Q2 2020 Results - Earnings Call Transcript
Assertio (ASRT) delivered earnings and revenue surprises of -100.00% and -18.62%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Assertio Holdings (NASDAQ:ASRT) moved higher by 0.9% in pre-market trading after the company reported Q2 results.
Assertio Therapeutics (NASDAQ: ASRT) will be releasing its next round of earnings this Friday, August 07.
Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LAKE FOREST, Ill., July 20, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, today announced that its second quarter 2...
Assertio Therapeutics, Inc. (ASRT) CEO Arthur Higgins on Q1 2020 Results - Earnings Call Transcript
Assertio (ASRT) delivered earnings and revenue surprises of 225.00% and 85.11%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Assertio Therapeutics (NASDAQ:ASRT) rose 9% in pre-market trading after the company reported Q1 results.
-- Completed Strategic Asset Sales of NUCYNTA® Franchise and Gralise® Totaling $502.5 Million -- -- Repaid Senior Secured Debt in Full and Successfully Tendered for Convertible Debt --
Assertio (ASRT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
LAKE FOREST, Ill., April 08, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today announced the completion and final results for its cash ...
Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million 1
LAKE FOREST, Ill., March 11, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today announces that it has commenced cash tender offers (the ...
Assertio Therapeutics, Inc. (ASRT) CEO Arthur Higgins on Q4 2019 Results - Earnings Call Transcript
Assertio (ASRT) delivered earnings and revenue surprises of -200.00% and 17.75%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
During Q4 earnings call, Assertio (ASRT) is likely to provide an update on its recently implemented cost-saving initiatives and the sales performance of its marketed drugs.
Assertio Therapeutics: A Biotech Stock Trading Below Its Cash Balance
Also Announces its Senior Secured Debt Has Been Repaid in Full Also Announces its Senior Secured Debt Has Been Repaid in Full
Assertio (ASRT) closed at $1.35 in the latest trading session, marking a -0.74% move from the prior day.
Company Intends to Use Cash Proceeds to Retire its Outstanding Debt
Assertio (ASRT) closed the most recent trading day at $1.05, moving +0.48% from the previous trading session.
Assertio (ASRT) closed the most recent trading day at $1.11, moving -0.89% from the previous trading session.
Is (ASRT) Outperforming Other Medical Stocks This Year?
LAKE FOREST, Ill., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or “The Company”) (NASDAQ: ASRT), today announced the closing of its previously disclosed agreeme...
Assertio (ASRT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Assertio (ASRT) inks a deal to sell Gralise to Alvogen for a total value of $127.5 million.
LAKE FOREST, Ill., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio”) (NASDAQ: ASRT), today announced it has entered into an agreement with Alvogen, a global privatel...
Assertio Therapeutics, Inc. (ASRT) CEO Arthur Higgins on Q3 2019 Results - Earnings Call Transcript
Assertio (ASRT) delivered earnings and revenue surprises of 4.35% and -6.93%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
LAKE FOREST, Ill., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT), today announced that its development partner West Therapeutic Development, LLC (West) has rec...
LAKE FOREST, Ill., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) announced today that Dr. David Wheadon has been appointed to the Company’s Board of Directors...
LAKE FOREST, Ill., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that members of senior management will participate at the Annual Cantor Fitzg...
Assertio Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Director, President and CEO of Assertio Therapeutics Inc (30-Year Financial, Insider Trades) Arthur J Higgins (insider trades) bought 50,000 shares of ASRT on 08/12/2019 at an average price of...
Assertio Therapeutics, Inc. (ASRT) CEO Arthur Higgins on Q2 2019 Results - Earnings Call Transcript
Assertio (ASRT) delivered earnings and revenue surprises of 8.70% and -2.20%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
About ASRT
Assertio Holdings operates as a specialty pharmaceutical company in the United States. Its specialty pharmaceutical products include CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for treating migraine; Zipsor, an NSAID for relief of mild to moderate acute pain; Gralise, a once-daily formulation of gabapentin for the management of postherpetic neuralgia; NUCYNTA ER, an extended-release version of tapentadol for the management of neuropathic pain associated with diabetic peripheral neuropathy; and NUCYNTA IR, an immediate release version... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Nov 5, 1997 |
| CEO Daniel A. Peisert | Employees 125 |
| Stock Exchange NASDAQ | Ticker Symbol ASRT |
Analyst Forecasts
According to 2 analysts, the average rating for ASRT stock is "Buy." The 12-month stock price forecast is 0.75, which is an increase of 17.28% from the latest price.